Raiffeisen Bank International AG Purchases Shares of 220,000 Cabaletta Bio, Inc. (NASDAQ:CABA)

Raiffeisen Bank International AG purchased a new position in Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 220,000 shares of the company's stock, valued at approximately $493,000. Raiffeisen Bank International AG owned approximately 0.45% of Cabaletta Bio as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Point72 Asset Management L.P. raised its position in shares of Cabaletta Bio by 89.7% during the 4th quarter. Point72 Asset Management L.P. now owns 1,265,882 shares of the company's stock valued at $2,874,000 after acquiring an additional 598,607 shares in the last quarter. Integral Health Asset Management LLC grew its position in shares of Cabaletta Bio by 11.1% during the 4th quarter. Integral Health Asset Management LLC now owns 500,000 shares of the company's stock valued at $1,135,000 after buying an additional 50,000 shares during the last quarter. Bridgeway Capital Management LLC acquired a new stake in Cabaletta Bio during the fourth quarter worth about $199,000. Cantor Fitzgerald L. P. acquired a new stake in Cabaletta Bio during the fourth quarter worth about $224,000. Finally, Bank of America Corp DE lifted its holdings in Cabaletta Bio by 14.2% in the fourth quarter. Bank of America Corp DE now owns 546,461 shares of the company's stock worth $1,240,000 after acquiring an additional 67,787 shares during the last quarter.

Cabaletta Bio Stock Performance

Shares of CABA stock traded down $0.04 during midday trading on Tuesday, reaching $1.88. 2,146,278 shares of the company were exchanged, compared to its average volume of 1,550,166. The company's 50 day moving average price is $1.37 and its two-hundred day moving average price is $2.19. The company has a market cap of $95.40 million, a P/E ratio of -0.87 and a beta of 2.72. Cabaletta Bio, Inc. has a 12 month low of $0.99 and a 12 month high of $13.50.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last announced its earnings results on Wednesday, May 21st. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.04). As a group, sell-side analysts predict that Cabaletta Bio, Inc. will post -2.34 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on CABA. Citigroup cut their price target on Cabaletta Bio from $17.00 to $13.00 and set a "buy" rating on the stock in a report on Friday. Guggenheim raised their target price on Cabaletta Bio from $23.00 to $25.00 and gave the company a "buy" rating in a research note on Thursday, May 15th. HC Wainwright reaffirmed a "buy" rating and issued a $25.00 price objective on shares of Cabaletta Bio in a report on Tuesday, April 1st. Morgan Stanley cut their price objective on shares of Cabaletta Bio from $30.00 to $22.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 1st. Finally, Wells Fargo & Company reduced their target price on shares of Cabaletta Bio from $6.00 to $3.00 and set an "equal weight" rating for the company in a research note on Tuesday, April 1st. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Cabaletta Bio presently has a consensus rating of "Buy" and an average price target of $20.33.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.